IL-17 and IL-22 have been shown to increase protection against certain bacteria and fungal
pathogens in experimental models. However, no human studies have demonstrated a …

In 1993, Malawi became the first African country to replace chloroquine with sulfadoxine-pyrimethamine
nationwide in response to high rates of chloroquine-resistant falciparum malaria…

Background Blood-stage malaria vaccines are intended to prevent clinical disease. The
malaria vaccine FMP2.1/AS02 A , a recombinant protein based on apical membrane antigen 1 (…

Investment in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequencing
in Africa over the past year has led to a major increase in the number of sequences that have …

There are many fundamental aspects of the immunobiology of Plasmodium falciparum
infections that are not fully understood, therefore limiting our comprehension of how people …

Immunity against schistosomes includes anti‐infection immunity, which is mainly active against
invading larvae in the skin, and anti‐disease immunity, which controls abnormal fibrosis …

Schistosome infection is a major public health concern affecting millions of people living in
tropical regions of Africa, Asia, and South America. Schistosomes cause mild clinical …

Background Heterogeneous patterns of malaria transmission are thought to be driven by
factors including host genetics, distance to mosquito breeding sites, housing construction, and …

Background The recent decline in malaria incidence in many African countries has been
attributed to the provision of prompt and effective anti-malarial treatment using artemisinin-…

Millions of humans are exposed to schistosome infections, which cause severe kidney and
liver disease and 280,000 deaths annually. Th2-mediated immunity is critical to human …